Finance

Lists
Q2 2027 earnings • released • EPS beat +1.32% • Revenue beat +4.70%
See results
AUROPHARMA:NSE
Aurobindo Pharma Ltd
₹1,705.00
+0.62%
(+10.50) 1D
Nov 4, 3:30:00 PM GMT+5:30  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for AUROPHARMA...
Open
₹1,698.00
High
₹1,724.60
Low
₹1,691.00
Mkt. cap
987.92B
Avg. vol.
855.72K
Volume
2.14M
P/E ratio
26.64
52-wk high
₹1,740.00
52-wk low
₹1,106.00
EPS
₹64.00
Shares outstanding
585.90M
No. of employees
29K
Open
₹1,698.00
High
₹1,724.60
Low
₹1,691.00
Mkt. cap
987.92B
Avg. vol.
855.72K
Volume
2.14M
P/E ratio
26.64
52-wk high
₹1,740.00
52-wk low
₹1,106.00
EPS
₹64.00
Shares outstanding
585.90M
No. of employees
29K
News stories
From web sources and news partners
Profile
Aurobindo Pharma Limited is an Indian multinational pharmaceutical manufacturing company based in HITEC City, Hyderabad, with U.S. headquarters in East Windsor, Mercer County, New Jersey. The company manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company's area of activity includes six major therapeutic and product areas: antibiotics, anti-retrovirals, cardiovascular products, central nervous system products, gastroenterologicals, and anti-allergics. The company markets these products in over 125 countries. Its marketing partners include Pfizer and AstraZeneca. Wikipedia
About Aurobindo Pharma Ltd
CEO-
Employees29.2K
Founded1986
HeadquartersHyderabad, Andhra Pradesh, India
SectorPharmaceutical industry
Industry-
Websiteaurobindo.com
Last report
Just released
Today, 10:00 PM
Fiscal period
Q2 2027
₹19.57 / ₹19.31
+1.32%beat
Revenue / Est. (INR)
102.63B / 98.02B
+4.70%beat
Fiscal Q2 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Revenue
Net income
All values in INR
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
82.86B
86.46B
88.53B
91.50B
Cost of goods sold
33.39B
34.81B
39.28B
36.27B
Cost of revenue
33.39B
34.81B
39.28B
36.27B
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
12.77B
13.10B
14.31B
14.80B
Operating expense
36.98B
38.56B
35.29B
41.29B
Total operating expenses
70.37B
73.37B
74.57B
77.56B
Operating income
12.49B
13.09B
13.96B
13.94B
Other non operating income
1.16B
1.54B
-2.51B
2.12B
EBT including unusual items
12.76B
13.39B
12.91B
15.15B
EBT excluding unusual items
12.76B
14.04B
13.59B
15.55B
Income tax expense
4.28B
4.29B
3.70B
4.83B
Effective tax rate
33.53%
32.03%
28.65%
31.88%
Other operating expenses
19.91B
20.81B
16.37B
21.62B
Net income
8.48B
9.10B
9.21B
10.33B
Net profit margin
10.24%
10.53%
10.41%
11.28%
Earnings per share
14.61
16.43
15.86
17.46
Interest and investment income
-
-
3.31B
-
Interest expense
-952.40M
-927.70M
-665.50M
-1.02B
Net interest expenses
-952.40M
-927.70M
2.65B
-1.02B
Depreciation and amortization charges
4.29B
4.65B
4.61B
4.87B
EBITDA
16.66B
16.71B
18.03B
18.01B
Gain or loss from assets sale
-
-
-
-
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps